Innate Pharma

Equities

IPH

FR0010331421

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 09:05:00 17/06/2024 pm IST			5-day change	1st Jan Change
2.025 ^EUR	-4.71%		-17.01%	-22.71%

08:03am	Innate: positive phase 1/2 data in leukemia	CF
07:00am	Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial	CI

Innate Pharma : Feuille de présence (in French)

May 24, 2024 at 09:16 pm IST

INNATE PHARMA

ASSEMBLEE MIXTE

23/05/2024

ARRETE DE LA FEUILLE DE PRESENCE

		Voix
	Actionnaires			Actions	Total Voix
		Simple	Double
Présents	20	1 230 307	268 320	1 364 467	1 498 627
Représentés	1	8 759	2 580	10 049	11 339
Pouvoir au président	13	13 386 933	685 800	13 729 833	14 072 733
Vote par correspondance	50	21 209 823	6 192	21 212 919	21 216 015
TOTAL	84	35 835 822	962 892	36 317 268	36 798 714

Certifié sincère et véritable, à MARSEILLE, le 23/05/2024

Le secrétaire

Le président

Les Scrutateurs

Mme Delphine DOISNE	Mme Irina STAATZ	M. Gilles BRISSON	M. Olivier MARTINEZ
	GRANZER

23/05/2024 12:10:54

Attachments

Original Link
Original Document
Permalink

Disclaimer

Innate Pharma SA published this content on 24 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 May 2024 15:45:16 UTC.

Latest news about Innate Pharma

Innate: positive phase 1/2 data in leukemia	11:33am	CF
Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial	10:30am	CI
Transcript : Innate Pharma S.A. - Special Call	11/06
Innate Pharma: positive data in mycosis fungoides	04/06	CF
Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides	04/06	CI
Innate Pharma: five abstracts selected for ASCO	24/05	CF
Transcript : Innate Pharma S.A., Q1 2024 Earnings Call, May 14, 2024	14/05
Sanofi: progress in hematology trial	15/04	CF
Innate Pharma: progress in hematology trial	15/04	CF
Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients	15/04	CI
Innate Pharma: IPH45 data presented at AACR	10/04	CF
Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate	10/04	CI
Transcript : Innate Pharma S.A., 2023 Earnings Call, Mar 21, 2024	21/03
Innate Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Innate Pharma initiates lymphoma trial	06/03	CF
Innate Pharma: abstract on IPH45 at the AACR congress	06/03	CF
Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin?s Lymphoma	06/03	CI
Global markets live: Next, Shell, GM, Apple, Nasdaq...	04/01
US FDA Ends Partial Clinical Hold on Innate Pharma's Investigational Cancer Drug	04/01	MT
Innate Pharma Says FDA Lifted Partial Clinical Hold on Lacutamab Clinical Program	04/01	MT
Innate Pharma: FDA suspension lifted	04/01	CF
Innate Pharma appoints two new board members	04/01	CF
Innate Pharma S.A. Announces Executive Changes	04/01	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	19/12	MT
Innate Pharma Shares Rise after Sanofi Exercises Licensing Option	19/12	DJ

Chart Innate Pharma

Duration

Period

More charts

Company Profile

Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding of NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and to forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi as well as a multi-product partnership with AstraZeneca. Revenues break down by source of income as follows: - revenues from collaboration and licensing agreements (84.2%); - government financing for research expenditure (15.8%). At the end of 2023, the company had a portfolio of 7 products in clinical development, including 1 in phase III (Monalizumab for the treatment of cancer), 2 in phase II (Lacutamab for the treatment of cutaneous T-cell lymphomas and IPH5201 for the treatment of cancer) and 4 in phase I (IPH5301 for the treatment of solid tumours, IPH6101 for the treatment of relapsed or refractory acute myeloid leukaemia, IPH6401 for the treatment of multiple myeloma and IPH6501 for the treatment of non-Hodgkin lymphoma).

Sector

Biotechnology & Medical Research

Calendar

25/06/2024 - H.C Wainwright Immune Cell Engager Virtual Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Innate Pharma

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.125 EUR

Average target price

6.475 EUR

Spread / Average Target

+204.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INNATE PHARMA	-22.71%	18Cr
MODERNA, INC.	+39.12%	5.37TCr
LONZA GROUP AG	+33.67%	3.89TCr
IQVIA HOLDINGS INC.	-8.29%	3.88TCr
CELLTRION, INC.	-10.77%	2.73TCr
ICON PUBLIC LIMITED COMPANY	+11.49%	2.59TCr
ALNYLAM PHARMACEUTICALS, INC.	-15.97%	2.03TCr
UNITED THERAPEUTICS CORPORATION	+34.17%	1.28TCr
MEDPACE HOLDINGS, INC.	+28.11%	1.22TCr
BIO-TECHNE CORPORATION	-2.86%	1.2TCr

Other Biotechnology & Medical Research